- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03590847
Time to Eat Study - Pilot
December 2, 2024 updated by: University of Florida
The goals of this pilot study is to evaluate the safety and feasibility of time restricted feeding in an older adult population.
Study Overview
Detailed Description
For this 4-week pilot study, the study team will recruit 10 overweight, older adults who are at risk for, or have, mobility impairment, as measured by slow gait speed and self-reported mobility difficulty and self-reported sedentary lifestyle.
All participants will receive the time restricted feeding intervention, which will consist of limiting the time in which food is consumed to 8 hours per day and fasting for 16 hours per day.
The study will also assess the variance of inflammatory markers, walking speed, physical and cognitive function, grip strength, body measurements, perceived fatigability, health related quality of life and activity level.
This allows the refinement of the design, recruitment yields, target population, adherence, retention, and tolerability of a larger scale study.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida Institute on Aging
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Consent to participate in the study
- Men and women ≥ 65 years old
- Self-reported difficulty walking ¼ mile or climbing a flight of stairs
- Self-reported sedentariness (<30 minutes structured exercise per week)
- Walking speed <1 m/sec on the 4 m walk test
- Able to walk unassisted (cane allowed)
- Have a body mass index between 25 - 40 kg/m2 (inclusive)
Exclusion Criteria:
Current dietary habits
- Fasting >12 hours per day
- Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake
- Weight loss > 5 lbs in the past month
Medical history or conditions
- Resting heart rate of >120 beats per minute, systolic blood pressure > 180 mmHg or diastolic blood pressure of > 100 mmHg
- Unstable angina, heart attack or stroke in the past 3 months
- Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure
- Rheumatoid arthritis, Parkinson's disease or currently on dialysis
- Active treatment for cancer in the past year
- Insulin dependent diabetes mellitus
- Taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart)
- Any condition that in the opinion of the investigator would impair ability to participate in the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intermittent fasting
Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
|
Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period.
Participants will be asked to record the time of first and final food/drink consumption each day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence
Time Frame: Week 4
|
Adherence to the study intervention is measured using food intake time diary.
Participants are considered compliant to the study intervention if he/she fasts between 14 - 18 hours per day for the duration of the 4 week study.
|
Week 4
|
|
Number of Participants With Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability
Time Frame: Week 4
|
At each follow-up contact (either by phone or in person), participants are asked about any changes to their health or physical function since the previous contact.
The changes are documented on the adverse event log.
|
Week 4
|
|
Retention
Time Frame: Week 4
|
Number of Participants who dropped out before the Week 4 clinic visit was completed.
|
Week 4
|
|
Recruitment Yields
Time Frame: Baseline
|
Recruitment yields is measured by the number of individuals who were assessed at phone screening.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Weight
Time Frame: Week 4
|
Body weight will be measured following the removal of excess clothing and shoes with calibrated scales.
Primary study outcomes include final weight at the 4 week assessment visit.
|
Week 4
|
|
Body Mass Index (BMI)
Time Frame: Week 4
|
Measure of body fat using weight from previous weight measurement.
|
Week 4
|
|
Waist Circumference
Time Frame: Week 4
|
Waist circumference is taken at the mid-point between the participant's lowest rib and the top of his/her hip bone.
|
Week 4
|
|
Blood Glucose
Time Frame: Week 4
|
Blood was drawn at a fasted state.
Glucose levels were measured by Quest Diagnostic Clinical Laboratories, which is accredited by the College of American Pathologists.
|
Week 4
|
|
Systolic Blood Pressure
Time Frame: Week 4
|
Resting blood pressure was taken after participants spent 5 min seated in a quiet room, free of distractions.
Blood pressure was obtained according to standardized protocol.
Three readings of blood pressure, spaced one minute apart, were taken using a sphygmomanometer with appropriate cuff size.
First reading was discarded and last two readings were averaged.
If large differences were observed between second and third readings, an additional reading was taken and the median value of the three trials was used.
|
Week 4
|
|
Diastolic Blood Pressure
Time Frame: Week 4
|
Resting blood pressure was taken after participants spent 5 min seated in a quiet room, free of distractions.
Blood pressure was obtained according to standardized protocol.
Three readings of blood pressure, spaced one minute apart, were taken using a sphygmomanometer with appropriate cuff size.
First reading was discarded and last two readings were averaged.
If large differences were observed between second and third readings, an additional reading was taken and the median value of the three trials was used.
|
Week 4
|
|
6 Minute Walk Test (Meters)
Time Frame: Week 4
|
The 6-Minute Walk Test (6MWT) measures the distance a participant can walk on a standard course within six minutes, without running or overexerting themselves.
Contraindications for test administration and stopping rules will be followed according to the guidelines of the American Thoracic Society.
The outcome will be reported in meters (m), representing the total distance covered during the 6-minute walk.
|
Week 4
|
|
6 Minute Walk Test (m/s)
Time Frame: Week 4
|
The 6 Minute Walk test measures the amount of distance the participant can complete on a standard walking course in six minutes without running or overexerting themselves.
Contraindications for test administration and stopping rules based on American Thoracic Society will be followed.
Walking speed was calculated by dividing number of meters walked by total time completed (360 seconds/6 minutes).
|
Week 4
|
|
Grip Strength (Dominant Hand)
Time Frame: Week 4
|
Isometric hand grip strength is a commonly used measure of upper body skeletal muscle function and has been widely used as a general indicator of functional status.Total force output is reported in kilograms (kg).
|
Week 4
|
|
12-Item Short Form Survey Physical Function (Summary Score)
Time Frame: Week 4
|
Self-administered, 12-item questionnaire to measure health-related quality of life.
Short form (SF) physical health status with scores on this measure ranging from 0 to 100, where greater scores represent better health.
|
Week 4
|
|
12-Item Short Form Survey Mental Function (Summary Score)
Time Frame: Week 4
|
Self-administered, 12-item questionnaire to measure health-related quality of life.
Short form (SF) mental health status with scores on this measure ranging from 0 to 100, where greater scores represent better health.
|
Week 4
|
|
12-Item Short Form Survey Total Score
Time Frame: Week 4
|
A self-administered, 12-item questionnaire is used to measure health-related quality of life, specifically the Short Form (SF) general health perception.
Scores range from 0 to 100, with higher scores indicating better perceived health.
Total scores are reported.
|
Week 4
|
|
Fatigability Questionnaire (Mental Subscale)
Time Frame: Week 4
|
A self-administered, 26-item questionnaire to measure perceived mental and physical fatigability.
Scores range from 0-50 on a scale where higher scores represent higher levels of fatigability.
|
Week 4
|
|
Fatigability Questionnaire (Physical Subscale)
Time Frame: Week 4
|
A self-administered, 26-item questionnaire to measure perceived mental and physical fatigability.
Scores range from 0-50 on a scale where higher scores represent higher levels of fatigability.
|
Week 4
|
|
Montreal Cognitive Assessment
Time Frame: Week 4
|
The Montreal Cognitive Assessment (MoCA) is a 30-point tool designed to assess mild cognitive impairment.
It evaluates various cognitive domains, including attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
The total score is obtained by summing the individual subscores, with a minimum score of 0 and a maximum score of 30.
Higher scores indicate better cognitive function.
To minimize learning effects from repeated administrations, different versions of the test were used at baseline and week four.
|
Week 4
|
|
Circulating (Plasma) microRNA
Time Frame: Week 4
|
The fold change in circulatory microRNA post-TRE regimen will be measured using the HTG EdgeSeq miRNA Whole Transcriptome Assay, which profiles the expression of circulatory miRNAs.
The total number of differentially expressed miRNAs will be analyzed, including a breakdown of how many were differentially upregulated and downregulated.
|
Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stephen Anton, PhD, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2018
Primary Completion (Actual)
September 5, 2018
Study Completion (Actual)
September 5, 2018
Study Registration Dates
First Submitted
June 8, 2018
First Submitted That Met QC Criteria
July 6, 2018
First Posted (Actual)
July 18, 2018
Study Record Updates
Last Update Posted (Actual)
December 6, 2024
Last Update Submitted That Met QC Criteria
December 2, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201801293
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight
-
National University Health System, SingaporeActive, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , ObesitySingapore
-
Carmen Lucas AbellánUniversidad Católica San Antonio de MurciaCompletedOverweight/Obesity | Overweight or Obese | Overweight or Obese Adults | Obesity and Overweight | Obese SubjectsSpain
-
University Hospital Bispebjerg and FrederiksbergUniversity of CopenhagenCompleted
-
Children's Hospital Los AngelesEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight AdolescentsUnited States
-
Empros Pharma ABNot yet recruitingOverweight or Obese | Obesity and Overweight
-
University of AarhusThe Danish Dairy Research Foundation, Denmark; Sygekassernes HelsefondCompletedOverweight and Obesity | Overweight Adolescents | Metabolic DiseaseDenmark
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsActive, not recruitingOverweight and Obesity | Overweight, Childhood | Overweight, InfantFrance
-
Medialis Ltd.RecruitingObesity & Overweight | Overweight (BMI > 25)United Kingdom
-
Federal University of Health Science of Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Active, not recruitingObesity & Overweight | Overweight (BMI > 25)Brazil
-
National Taiwan University HospitalCompleted
Clinical Trials on Intermittent Fasting
-
H. Lee Moffitt Cancer Center and Research InstituteNot yet recruitingPancreatitis | Pancreatitis, Chronic | Pancreatitis, Acute | Pancreas Disease | Acute Recurrent PancreatitisUnited States
-
Mahidol UniversityHealth Systems Research InstituteEnrolling by invitationWeight Loss | Obese | Intermittent Fasting | Behavioral Economic | HOMA-IRThailand
-
Ohio State UniversityNational Psoriasis FoundationCompletedPsoriasis | Psoriatic ArthritisUnited States
-
Université Libre de BruxellesRecruitingQuality of Life | Fatigue | Sleep Quality | Intermittent FastingBelgium
-
M.D. Anderson Cancer CenterNot yet recruitingPancreatic Cancer | Intermittent Fasting | EvaluatingUnited States
-
Menoufia UniversityRecruitingLocally Advanced Breast Cancer | Intermittent FastingEgypt
-
University of CalgaryCrohn's and Colitis FoundationNot yet recruiting
-
Washington University School of MedicineCompletedRelapsing Remitting Multiple SclerosisUnited States
-
Charite University, Berlin, GermanyWestfälische Wilhelms-Universität MünsterCompleted
-
Istanbul Training and Research HospitalCompleted